IMPC Embryo Phenotyping – Goals and Procedures

With up to one third of knockout strains being embryonic lethal, a systematic unbaised phenotyping pipeline was established to perform morphologic and imaging evaluation of mutant embryos to define the primary perturbations that cause their death. From this important insights are gained into gene function.

IMPC centers funded by the NIH Common fund mechanism are delivering the following for All Lines:

  • Viability
  • Heterozygote E12.5 Embryonic LacZ staining ( 2 mutant animals, wt reference images)

For All Embryonic Lethal Lines, gross morphology is assessed at E12.5 to determine if defects occur earlier or later in development. A comprehensive imaging platform is then used to assess dysmorphology at the most appropriate stage:


Procedure Number Note
E9.5 Gross morphology at least 2 homs,2 wt images optional
E9.5 OPT screening at least 2 homs reconstructions available
E14.5-E15.5 Gross morphology at least 2 homs, 2 wt images optional
E14.5-E15.5 microCT screening at least 2 homs reconstructions available
E14.5 HREM at least 3 homs, 1wt reconstructions available
E18.5 Gross morphology at least 2 homs images optional
E18.5 microCT at least 2 homs, 2 wt reconstructions available

In addition, the NIH is supporting in-depth phenotyping of embryonic lethal lines with three current awardees.

Trevor William, University of Colorado School of Medicine

Jesse Mager, University of Massachusetts Amherst

Elizabeth Lacy, Memorial Sloan Kettering Cancer Center

Dr. Jeremy Reiter, University of California San Francisco